MedTrace Logo

Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

NCT00504452 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2011-11-07

No results posted yet for this study

Summary

The primary purpose of the study is to investigate the safety and efficacy of KP-1461 given every 12 hours for 124 days to HIV+ patients who have failed multiple antiretroviral regimens.

Conditions

  • HIV Infections

Interventions

DRUG

KP-1461

Oral dosage, 1600 mg bid for 124 days

Sponsors & Collaborators

  • Koronis Pharmaceuticals.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-09-30
Completion
2009-06-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504452 on ClinicalTrials.gov